its software internationally, he says.
Fernandez says the amount of patients in the U.S. and other countries with sleep apnea is likely to increase in coming years, due to factors such as rising obesity rates and the aging Baby Boomer generation. The number of people who work as sleep specialists is unlikely to keep pace, he says, which could enhance the value of automated scoring software to sleep clinics.
One of EnsoData’s direct competitors is Canada-based Cerebra Health, which acquired the sleep software startup Michele late last year. Another is Philips Respironics, whose line of sleep medicine products includes its Somnolyzer devices.
Eventually, EnsoData envisions broader applications for its digital tools, Fernandez says.
“We’re taking a harder look at some [areas beyond sleep medicine], in particular critical care, post-surgical care, home health, neurology, and cardiology,” he says. “We hope to provide an update on our second product in early 2019.”
